Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE